SOPHiA GENETICS (SOPH) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 31, 2026

Net selling: insiders sold $2.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$2.3M netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, latest quarter: NoneNo large changes

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about SOPH filings

Are insiders buying or selling Sophia Genetics SA (SOPH) stock?

Net selling: insiders sold $2.3M and bought $0 of SOPH stock on the open market in the 90 days to Oct 31, 2026, according to SEC Form 4 filings. $2.3M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Camblong, Jurgi (Executive Chairman), who sold $801K. The latest filing was on Oct 14, 2026.

Which members of Congress have traded SOPH recently?

None. No member of Congress disclosed a SOPH trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SOPH smart-money data?

This summary uses filings available on Oct 31, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Smart money on SOPH

Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $127K
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
No recent fund filings found
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about SOPH filings

Are insiders buying or selling Sophia Genetics SA (SOPH) stock?

Which members of Congress have traded SOPH recently?

None. No member of Congress disclosed a SOPH trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SOPH smart-money data?

Insiders

What insiders are doing

12 trades · 6 mo

Sold$796K

Sells (3)

CJ
Camblong Jurgi
Executive Chairman · Cluster · Oct 14
$62K
sold
MP
Menu Philippe
Chief Medical Officer · Cluster · Oct 14
$36K
sold
XZ
Xu Zhenyu
Chief Scientific Officer · Cluster · Oct 14
$29K
sold

2 more trades

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 2 trades

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 4, 2026

Earnings came in 11.0% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 4, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.20+10.95% beat

-$0.22 expected

Revenue

$23.3M

Financial statements: Alpha Vantage

EPS: Yahoo Finance

Next report

Estimated report: Nov 3, 2026, in 3 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 4, 2026	-$0.20est. -$0.22	+10.95%beat	$23.3MAlpha Vantage	+27.2%from $18.3M
Mar 31, 2026Reported May 5, 2026	-$0.19est. -$0.24	+20.42%beat	$21.7MAlpha Vantage	+22.0%from $17.8M
Dec 31, 2025Reported Mar 3, 2026	-$0.17est. -$0.20	+14.64%beat	$21.7MAlpha Vantage	+22.4%from $17.7M
Sep 30, 2025Reported Nov 4, 2025	-$0.20est. -$0.20	+1.65%beat	$19.5MAlpha Vantage	+22.8%from $15.9M
Jun 30, 2025Reported Aug 5, 2025	-$0.25est. -$0.17	-47.06%miss	$18.3MAlpha Vantage	+15.9%from $15.8M
Mar 31, 2025Reported May 6, 2025	-$0.18est. -$0.19	+5.26%beat	$17.8MAlpha Vantage	+12.7%from $15.8M
Dec 31, 2024Reported Mar 4, 2025	-$0.12est. -$0.15	+20.07%beat	$17.7MAlpha Vantage	+4.0%from $17.0M
Sep 30, 2024Reported Nov 5, 2024	-$0.21est. -$0.18	-16.67%miss	$15.9MAlpha Vantage	-2.8%from $16.3M

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

52-wk high: $8.98
52-wk low: $3.83
Prev close: $7.97
Mkt cap: $678.5M
ROE: -101.2%
Beta: 0.95
P/S: 7.9x
P/B: 8.2x
Profit margin: -93.9%
Op margin: -85.0%

Sep 2025 to Jun 2026

What it sold, what it cost, what was left.

RevenueProfit

Sep 2025Dec 2025Mar 2026Jun 2026

Income statement, 4 periods, all values in US dollars
USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
What came in
RevenueTotal revenue	$19.5M	$21.7M	$21.7M	$23.3M
Cost of what it soldCost of revenue	$6.6M	$7.0M	$6.9M	$8.2M
Gross profit	$12.9M	$14.7M	$14.7M	$15.1M
What it spent
Research and development	$9.4M	$8.5M	$11.1M	$8.7M
Sales and adminSelling, general and administrative	$13.9M	$22.0M	$13.8M	$15.2M
Other operating costsOperating costs not itemised in the filing's summary	$7.5M	$2.2M	$7.2M	$11.2M
Total operating expenses	$30.8M	$32.7M	$32.0M	$35.1M
What was left
Operating profitOperating income	-$17.9M	-$18.0M	-$17.3M	-$20.1M
Interest on debtInterest expense	$1.7M	$1.7M	$1.7M	$1.6M
Profit before tax	-$19.4M	-$19.6M	-$19.1M	-$22.3M
TaxIncome tax expense	$642.0K	-$395.0K	$253.0K	$78.0K
Net profitNet income	-$20.0M	-$19.2M	-$19.3M	-$22.4M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$15.9M	-$15.5M	-$14.7M	-$17.8M

Technicals

Price structure

This stock is in a strong uptrend.

Trend

Strong uptrend

80 / 100

RSI 14

58balanced

20D volatility

70%annualized

52-week range

$7.97

$3.83$8.98

20D support

$6.39recent floor

20D resistance

$8.56recent ceiling

Returns

5D +13.0%20D -0.7%60D +26.5%

Price vs moving averages

SMA20 +8.5%SMA50 +1.0%SMA200 +34.2%

Volume pace

0.88xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Jun 30, 2026Aug 4, 2026

-$0.20est. -$0.22

+10.95%

$23.3MAlpha Vantage

+27.2%from $18.3M

Mar 31, 2026May 5, 2026

-$0.19est. -$0.24

+20.42%

$21.7MAlpha Vantage

+22.0%from $17.8M

Dec 31, 2025Mar 3, 2026

-$0.17est. -$0.20

+14.64%

$21.7MAlpha Vantage

+22.4%from $17.7M

Sep 30, 2025Nov 4, 2025

-$0.20est. -$0.20

+1.65%

$19.5MAlpha Vantage

+22.8%from $15.9M

Jun 30, 2025Aug 5, 2025

-$0.25est. -$0.17

-47.06%

$18.3MAlpha Vantage

+15.9%from $15.8M

Mar 31, 2025May 6, 2025

-$0.18est. -$0.19

+5.26%

$17.8MAlpha Vantage

+12.7%from $15.8M

Dec 31, 2024Mar 4, 2025

-$0.12est. -$0.15

+20.07%

$17.7MAlpha Vantage

+4.0%from $17.0M

Sep 30, 2024Nov 5, 2024

-$0.21est. -$0.18

-16.67%

$15.9MAlpha Vantage

-2.8%from $16.3M

Income statement, 4 periods, all values in US dollars
USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
What came in
RevenueTotal revenue	$19.5M	$21.7M	$21.7M	$23.3M
Cost of what it soldCost of revenue	$6.6M	$7.0M	$6.9M	$8.2M
Gross profit	$12.9M	$14.7M	$14.7M	$15.1M
What it spent
Research and development	$9.4M	$8.5M	$11.1M	$8.7M
Sales and adminSelling, general and administrative	$13.9M	$22.0M	$13.8M	$15.2M
Other operating costsOperating costs not itemised in the filing's summary	$7.5M	$2.2M	$7.2M	$11.2M
Total operating expenses	$30.8M	$32.7M	$32.0M	$35.1M
What was left
Operating profitOperating income	-$17.9M	-$18.0M	-$17.3M	-$20.1M
Interest on debtInterest expense	$1.7M	$1.7M	$1.7M	$1.6M
Profit before tax	-$19.4M	-$19.6M	-$19.1M	-$22.3M
TaxIncome tax expense	$642.0K	-$395.0K	$253.0K	$78.0K
Net profitNet income	-$20.0M	-$19.2M	-$19.3M	-$22.4M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$15.9M	-$15.5M	-$14.7M	-$17.8M

USD

Sep 2025

Dec 2025

Mar 2026

Jun 2026

What came in

RevenueTotal revenue

$19.5M

$21.7M

$23.3M

Cost of what it soldCost of revenue

$6.6M

$7.0M

$6.9M

$8.2M

Gross profit

$12.9M

$14.7M

$15.1M

What it spent

Research and development

$9.4M

$8.5M

$11.1M

$8.7M

Sales and adminSelling, general and administrative

$13.9M

$22.0M

$13.8M

$15.2M

Other operating costsOperating costs not itemised in the filing's summary

$7.5M

$2.2M

$7.2M

$11.2M

Total operating expenses

$30.8M

$32.7M

$32.0M

$35.1M

What was left

Operating profitOperating income

-$17.9M

-$18.0M

-$17.3M

-$20.1M

Interest on debtInterest expense

$1.7M

$1.6M

Profit before tax

-$19.4M

-$19.6M

-$19.1M

-$22.3M

TaxIncome tax expense

$642.0K

-$395.0K

$253.0K

$78.0K

Net profitNet income

-$20.0M

-$19.2M

-$19.3M

-$22.4M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$15.9M

-$15.5M

-$14.7M

-$17.8M

Sophia Genetics SA

Smart money at a glance

What do analysts expect?

Questions about SOPH filings

Smart money on SOPH

Questions about SOPH filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 11.0% above what analysts expected.

Estimated report: Nov 3, 2026, in 3 days

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Sophia Genetics SA

Smart money at a glance

What do analysts expect?

Questions about SOPH filings

Smart money on SOPH

Questions about SOPH filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 11.0% above what analysts expected.

Estimated report: Nov 3, 2026, in 3 days

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Sophia Genetics SA

Overview

Questions about SOPH filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Sophia Genetics SA

Overview

Questions about SOPH filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.